ANGLE has completed a placing of new ordinary shares
ANGLE Plc has raised funds to develop the company.
ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.
Talk to the deal team
Related deals
EuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreMEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn moreElectro Optic Systems has acquired the UK interceptor business of MARSS
Electro Optic Systems Holdings Limited (ASX: EOS) has acquired the UK-based interceptor unmanned aerial system business of MARSS Group for US$6.4 million (€5.5 million). The interceptor is a reusable electric drone effector guided by imaging sensors and AI, which EOS will integrate into its counter-drone portfolio for defense and critical infrastructure customers. EOS plans further investment to complete development.
Learn more